B6;129-Cd79b^tm1Gzmn/J

Stock number: 008821
Product name: IgB AA knock-in , IgB Y2A , IgbetaAA
Research areas: Immunology, Inflammation and Autoimmunity Research

Description

Developing B cells in these CD79B antigen (Igβ AA) targeted mutant mice have higher levels of surface IgM and IgD on immature and recirculating B cells than wildtype mice. They also show a five-fold reduction in the number of B1a B cells in the peritoneal cavity.

Detailed description

Cytoplasmic tyrosines 195 and 206, associated with immune receptor tyrosine activation motifs (ITAMs), were replaced with alanine in this Ig beta targeted mutant strain. The only reported reproducible differences in developing B cells in these Igβ AA mutant mice is a higher level of surface IgM and IgD on immature and recirculating B cells. Igβ AA mice also show a five-fold reduction in the number of B1a B cells in the peritoneal cavity. This strain may be useful in studies of B cell receptor signaling.

Development

TAT (tyrosine) codons at positions 195 and 206 in the cytoplasmic tail of the gene were replaced with GCT (alanine). A loxP-flanked neomycin-resistance gene was used for positive selection. The mutation was created in 129/Sv-derived embryonic stem cells. The loxP segment was excised through crosses with an EIIa promoter germline Cre strain on a C57BL/6 background. This line was backcrossed to C57BL/6 three times by the donating laboratory.

Allele

Symbol: Cd79b^tm1Gzmn
Name: targeted mutation 1, Anna Gazumyan
MGI accession ID: MGI:3722155
Generation method: Targeted
Synonyms: IgbetaAA
Marker symbol: Cd79b
Marker name: CD79B antigen
Marker synonyms: AGM6; B29; Igb; Igbeta; Ig-beta
Chromosome: 11
Strain of origin: 129/Sv
Molecular note: Tyrosines 195 and 206 were replaced with alanines. A floxed neo was included in the vector and subsequently removed via cre mediated recombination.